Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation

T. Mori, S. Mori, Y. Kanda, K. Yakushiji, S. Mineishi, Y. Takaue, H. Gondo, M. Harada, H. Sakamaki, T. Yajima, Y. Iwao, T. Hibi, S. Okamoto

Research output: Contribution to journalArticle

79 Citations (Scopus)


To evaluate the clinical significance of a cytomegalovirus (CMV) antigenemia assay in the prediction and diagnosis of CMV gastrointestinal (CMV-GI) disease after hematopoietic stem cell transplantation (HSCT), 19 allogeneic HSCT recipients developing CMV-GI disease were retrospectively reviewed. All patients were monitored by a CMV antigenemia assay, at least once weekly after engraftment. The median onset of CMV-GI disease occurred 31 days post transplant (range: 19-62). Only four of 19 patients (21%) developed a positive CMV antigenemia test before developing CMV-GI diseases. Although all 19 patients subsequently developed positive CNIV antigenemia tests during their clinical courses, the values remained at a low-level in nine (47%) patients. Among the 14 patients in whom results of real-time polymerase chain reaction (PCR) were available, seven (50%) yielded positive results of real-time PCR before developing CMV-GI disease. In contrast to the values of CMV antigenemia, all 14 patients exclusively yielded high viral loads (median: 2.8 × 104 copies/ml plasma). We conclude that CMV antigenemia testing has limited value in prediction or early diagnosis of CMV-GI disease, and that real-time PCR could have a more diagnostic significance.

Original languageEnglish
Pages (from-to)431-434
Number of pages4
JournalBone Marrow Transplantation
Issue number4
Publication statusPublished - 2004 Feb 1



  • CMV antigenemia
  • Cytomegalovirus
  • Gastrointestinal disease
  • Hematopoietic stem cell transplantation
  • Real-time PCR

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this